BioCryst Pharmaceuticals BCRX Cash Provided by (Used in) Operating Activity, Including Discontinued Operation
Cash Provided by (Used in) Operating Activity, Including Discontinued Operation at other companies
Other financials
Where this comes from
Reported directly by BioCryst Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities.
The official record: BioCryst Pharmaceuticals’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →
Ask your AI about BioCryst Pharmaceuticals's cash provided by (used in) operating activity, including discontinued operation.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is BioCryst Pharmaceuticals's cash provided by (used in) operating activity, including discontinued operation?
- BioCryst Pharmaceuticals (BCRX) reported cash provided by (used in) operating activity, including discontinued operation of -$61.79M in Q1 2026.
- How has BioCryst Pharmaceuticals's cash provided by (used in) operating activity, including discontinued operation changed year-over-year?
- BioCryst Pharmaceuticals's cash provided by (used in) operating activity, including discontinued operation decreased by 124.6% year-over-year, from -$27.52M to -$61.79M.
- What is the long-term trend for BioCryst Pharmaceuticals's cash provided by (used in) operating activity, including discontinued operation?
- Over 3 years (2021 to 2025), BioCryst Pharmaceuticals's cash provided by (used in) operating activity, including discontinued operation has grown at a 34.7% compound annual growth rate (CAGR), from -$142.16M to $347.37M.
- What does cash provided by (used in) operating activity, including discontinued operation mean?
- Measures the cash generated from the company's core business operations, excluding financing and investing activities. It reflects the ability of the company to convert revenue into actual cash flow after accounting for changes in working capital.